{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-080027","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2022-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.415059+00:00","generated_at":"2026-06-26T21:24:00.165399+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Athira Pharma appoints Dr. Michael Panzara to board effective March 18, 2022","bullets":["Dr. Panzara, CMO at Wave Life Sciences, appointed Class I director with term expiring at 2024 annual meeting.","He brings over 20 years CNS drug development experience, including leadership at Sanofi Genzyme and Biogen.","Compensation includes initial stock option grant; no transactions with the company or its affiliates.","Press release notes his role in global regulatory approvals of MS drugs LEMTRADA, AUBAGIO, and TYSABRI."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-080027","json":"https://secwatch.observer/filing/0001193125-22-080027.json","markdown":"https://secwatch.observer/filing/0001193125-22-080027.md","text":"https://secwatch.observer/filing/0001193125-22-080027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/0001193125-22-080027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/d277480d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:24:00.165399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65da088bfb","claim":"Michael Panzara was appointed as director at LeonaBio, Inc..","evidence_excerpt":"appointed Dr. Michael Panzara as a director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/0001193125-22-080027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}